SAN DIEGO – MAY 23, 2007 – Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ) announced today that DAYTRANA™ (methylphenidate transdermal system), its Attention Deficit Hyperactivity Disorder (ADHD) patch, ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window A transdermal ...

BOSTON – OCTOBER 25, 2007 – Shire plc (LSE: SHP, NASDAQ: SHPGY, TSX: SHQ), the global specialty biopharmaceutical company, announced that data from a 12-month study of DAYTRANATM (methylphenidate ...

WASHINGTON - The FDA on Thursday approved the first skin patch to treat attention deficit hyperactivity disorder in children. Called Daytrana, the patch is designed to be worn for nine hours and ...

WASHINGTON - A federal advisory panel determined Friday that the first skin patch to treat attention deficit hyperactivity disorder in children is effective and safe, bringing it a step closer to ...

MIAMI (CBS.MW) - Shares of Noven Pharmaceuticals slid 32 percent Monday after the company said it'll delay seeking marketing approval for its skin patch that treats Attention Deficit Hyperactivity ...

NEW YORK (Reuters Health) - Smoking during pregnancy has been linked to a higher chance of the child having attention-deficit/hyperactivity disorder (ADHD), and a new ...

The panellists said the product should be approved, and crucially stopped short of restricting use of the product to second-line therapy after a patient had already tried oral methylphenidate ...

Patients and prescribers alike are familiar with the vast array of psychiatric medicines available to treat mental illnesses. They are often less aware that certain psychotropics can be delivered via ...

An article in the Philadelphia Inquirer on a new medicated patch for children with ADHD reports William Pelham, professor of psychology and pediatrics, conducted two trials of the patch. Go to article ...